What does the drug do?
Tauroursodeoxycholic acid (TUDCA) is a substance naturally produced by the body and found in small trace amounts in bile. TUDCA works by camouflaging a stress chemical that triggers a chemical cascade that results in the death of a distressed or damaged cell. TUDCA is currently licensed to be used as a treatment in certain diseases of the liver in the USA. However, there is a growing body of evidence to suggest that TUDCA might be a potential therapeutic drug for a number of neurodegenerative diseases.
Phase 3 (TUDCA-ALS)
The Phase 3 clinical trial will look at the safety and efficacy of taking TUDCA in combination with riluzole over a long period of time (18 months). The trial will recruit 440 people recently diagnosed with ALS across 26 centres across Italy, Germany, UK, France, Belgium, the Netherlands and Ireland. You can find out more about the trial here.
How can I take part in the trial?
This trial is fully recruited and is no longer accepting new participants.
October 2023 - The clinical trial has been completed. Data analysis will commence imminently, with top line results expected to be announced in early 2024. The open-label extension phase of the trial is still ongoing.
Feb 2022 - The final participant was randomized into the trial. You can read more here.
Last updated: 03/10/2023